Posted by Michael Wonder on 29 May 2020
Roche’s Ocrevus (ocrelizumab) shorter 2 hour infusion time approved in Europe
28 May 2020 - Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosis.
Roche today announced EMA approval of a new, shorter two hour Ocrevus (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis.
The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
